Geron Corp. : Geron Announces Presentations at the American Association for Cancer Research Annual Meeting

 Geron Corp. : Geron Announces Presentations at the American Association for
                        Cancer Research Annual Meeting

MENLO PARK, Calif., April 9, 2013 - Geron Corporation (Nasdaq: GERN) today
announced presentation of the final results from the Phase 2 study of
imetelstat, the company's first-in-class telomerase inhibitor, as maintenance
therapy following platinum-based induction chemotherapy in patients with
advanced non-small cell lung cancer (NSCLC) at the American Association for
Cancer Research (AACR) 2013 Annual Meeting, currently taking place in
Washington, D.C.

In September 2012, top-line results for the overall study population reported
only a minimal impact on progression-free survival (PFS) in NSCLC patients who
received imetelstat. Using a retrospective measurement of tumor telomere
length, a preliminary subgroup analysis of NSCLC patients suggested that
patients whose tumors had short telomeres at baseline experienced an increase
in PFS when treated with imetelstat in comparison to patients in the control
arm. In a recently completed updated subgroup analysis using a refined
prospective assay to measure tumor telomere length and more mature clinical
data, the magnitude of the treatment effect in patients whose tumors had short
telomeres was not reproduced.

The final data from the Phase 2 study, including the results from the recent
updated subgroup analysis, will be presented in two posters:

Title: Improved Progression-Free Survival (PFS) in Patients with Short Tumor
Telomere Length: Subgroup Analysis from a Randomized Phase 2 Study of the
Telomerase Inhibitor Imetelstat as Maintenance Therapy for Advanced NSCLC
Date & Time: Tuesday, April 9, 8:00 a.m. - 12:00 p.m. ET
Abstract #: 2376
Location: Hall A-C, Poster Section 1

Title: A Randomized Phase 2 Study of the Telomerase Inhibitor Imetelstat as
Maintenance Therapy for Advanced Non-Small Cell Lung Cancer
Date & Time: Wednesday, April 10, 8:00 a.m. - 12:00 p.m. ET
Abstract #: 4660
Location: Hall A-C, Poster Section 2

In accordance with AACR publication rules, the posters will be made available
on the company's website at www.geron.com concurrently with the date and time
of the conference presentations.

About Imetelstat

Imetelstat is a potent and specific inhibitor of telomerase. This
first-in-class compound is a specially designed and modified short
oligonucleotide, which targets and binds directly and with high affinity to
the active site of telomerase. Unique and proprietary oligonucleotide
chemistry improves binding affinity and stability in plasma and tissues. A
lipid modification enables cellular and tissue penetration and
biodistribution.

To date, clinical data from Phase 2 studies indicate that imetelstat has
activity against hematologic malignancies, specifically essential
thrombocythemia, which provides clinical rationale for evaluating imetelstat
as a potential treatment for other hematologic myeloid malignancies where
there is a greater unmet need. Imetelstat is being currently evaluated in
patients with myelofibrosis through an investigator-sponsored trial conducted
at the Mayo Clinic.

About Geron

Geron is a biopharmaceutical company developing first-in-class therapies for
cancer, including its telomerase inhibitor, imetelstat, in clinical
development. For more information about Geron, visit www.geron.com.

CONTACT:

Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765
investor@geron.com
media@geron.com

                                     ###

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Geron Corp. via Thomson Reuters ONE
HUG#1691429